Industry

Microbiome therapy hits Phase 3 milestone: MaaT Pharma’s Xervyteg delivers in refractory GI-aGvHD ahead of ASH 2025 and EMA review

At the 67th ASH, one of hematology’s biggest stages, the Lyon-based biotech will present pivotal Phase 3 results that can bend treatment paradigms.

Health Canada Authorizes Functional Claims for SynbÆctive® ProBeautyShield

ProBeautyShield by SynBalance is an innovative probiotic complex developed to support and protect skin health.

Synbiotic supplementation improves symptoms in patients with post-COVID-19 chronic fatigue syndrome: results from a randomized placebo‑controlled clinical trial

Taking the synbiotic mixture for three months appeared to boost the body’s metabolism and mitigates some of the main symptoms of post-COVID fatigue syndrome.

Bayer bets on biotics: new Darmstadt lab to fast-track microbiome-based health solutions

The next wave of gut health products won’t just claim to be natural — they’ll be microbiome-powered and science-certified.

Danone opens OneBiome Lab at Paris-Saclay: where the microbiome meets AI

The race toward evidence-based microbiome nutrition has just found its new headquarters.

ROELMI BIOTECH: a new production hub for precision biofermentation in Italy

The company is now taking a decisive step from laboratory-scale research to industrial-scale biofermentation.

Synbiotics and autism: a novel microbiome-based strategy to improve gut and behavioral health in children with autism spectrum disorder 

A study demonstrates that synbiotic supplementation, alone or combined with GDH, is a safe and effective adjunct therapy for autistic children with DGBI.

Novonesis and Novo Nordisk Join Forces to Harness the Gut Microbiome for Metabolic Health

The combination of biological innovation and pharmaceutical muscle could create a unique pathway for translating microbiome discoveries into accessible, science-backed solutions for everyday health.

Engineering the gut: Endure Biotherapeutics secures NIH funding for groundbreaking FAP therapy

New funding boosts development of microbiome-based therapies for hereditary cancer risk, opening paths to alternatives beyond surgery.

A $2.5 billion catalyst: how the Gates Foundation is redefining women’s health innovation—with the microbiome in the spotlight

The Bill & Melinda Gates Foundation accelerates research and innovation targeting the most neglected areas of female health.

Subscribe to MicrobiomePost newsletter

Take full advantage of MicrobiomePost‘s features.

Scroll to Top